News
October 13, 2021
Aluda Pharmaceuticals announces results for a novel anti-COVID agent with both anti-viral and anti-inflammatory actions
July 16, 2021
Aluda Pharmaceuticals announces peer-reviewed publication on ALD-R491, an Exosome Release Inhibitor and novel oncology mechanism
January 20, 2020
Aluda: targeting the fundamentals. Aluda begins to unveil pipeline, starting with first-in-class anti-vimentin program for fibrosis
This document was printed from http://www.aludapharm.com/company/news.html